William E Brady
Overview
Explore the profile of William E Brady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farley J, Brady W, OMalley D, Fujiwara K, Yonemori K, Bonebrake A, et al.
Gynecol Oncol
. 2022 Oct;
167(3):423-428.
PMID: 36244829
Objective: The primary objective of the study was to estimate the 12-month progression-free survival (PFS) for carboplatin/paclitaxel + temsirolimus in women with newly diagnosed clear cell ovarian cancer (CCOC), compared...
2.
Gershenson D, Miller A, Brady W, Paul J, Carty K, Rodgers W, et al.
Lancet
. 2022 Feb;
399(10324):541-553.
PMID: 35123694
Background: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK...
3.
Elmore A, Harris W, Mu L, Brady W, Hovey K, Mares J, et al.
Eur J Nutr
. 2022 Jan;
61(3):1585-1594.
PMID: 34988653
Purpose: To evaluate the relationship between red blood cell (RBC) polyunsaturated fatty acid (PUFA) levels, and dietary PUFA and fish intake, with prevalent and incident age-related macular degeneration (AMD) in...
4.
Sahli M, Ochs-Balcom H, Moeller S, Brady W, Tolford T, Millen A
Optom Vis Sci
. 2020 Aug;
97(8):598-605.
PMID: 32833404
Significance: Lifestyle influences eye health and other chronic diseases. All health care providers, not just primary care physicians, should have the necessary information and training to advise and refer patients...
5.
Huh W, Brady W, Fracasso P, Dizon D, Powell M, Monk B, et al.
Gynecol Oncol
. 2020 Jul;
158(3):562-569.
PMID: 32641240
Objective: Women with persistent, recurrent, and/or metastatic cervical cancer have a poor prognosis. Even with the availability of cisplatin plus paclitaxel and bevacizumab, median overall survival (OS) is only 17.0 ...
6.
Plunkett R, Barone T, Brady W, Attwood K, Prasad D
J Clin Neurosci
. 2019 Jul;
68:117-122.
PMID: 31340886
Brain metastasis (BM) is a common neurologic complication of cancers such as lung, breast, and melanoma. Recently, there has been a shift in treatment of BM from whole brain radiation...
7.
Gore M, Hackshaw A, Brady W, Penson R, Zaino R, McCluggage W, et al.
Gynecol Oncol
. 2019 Apr;
153(3):541-548.
PMID: 31005287
Objectives: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer. Methods: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC:...
8.
Boardman C, Brady W, Dizon D, Kunos C, Moore K, Zanotti K, et al.
Gynecol Oncol
. 2018 Sep;
151(2):202-207.
PMID: 30174176
Background: Chemo-radiation (chemoRT) has improved the overall survival for locally advanced cervical cancer (LACC) though women whose disease involves the para-aortic nodes (PAN) experience recurrence rates and worse survival outcomes...
9.
Shah R, Xia C, Krailo M, Amatruda J, Arul S, Billmire D, et al.
Gynecol Oncol
. 2018 Jun;
150(2):253-260.
PMID: 29884437
Objective: Dysgerminoma is the most common malignant ovarian germ cell tumor (GCT) with peak incidence during adolescence and young adulthood. Current standard of care for patients with disease that has...
10.
Konstantinopoulos P, Brady W, Farley J, Armstrong A, Uyar D, Gershenson D
Gynecol Oncol
. 2018 May;
150(1):9-13.
PMID: 29739622
Objective: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. Methods: Patients with recurrent ovarian, fallopian or primary peritoneal tumors...